Verso Capital turns spin-offs into fast growers – Read the success stories!

Verso Capital, a Helsinki-based buyout investor, has raised a new €100 million private equity fund that seeks to invest in spin-offs and other businesses not living up to their full potential in their current ownership.

Verso Capital acquires and accelerates spin-offs with a new €100 million fund

The new €100 million fund acquires businesses that have strong growth potential but are not living up to their full potential in the current ownership.

Verso Capital – Building international growth

Verso Capital is a growth stage buy-out investor focusing on European B2B businesses. We invest primarily into businesses that have up to 50M of revenue, but currently have growth bottlenecks hindering business performance.

We are an active investor: we help accelerate the growth of the business, working with the management as a team. We are looking for business operations to carve out from larger companies, and growth companies that are ready to take growth leaps.

We specialise in carve-out situations

Verso Capital is specialised in growth stage carve-outs in Europe. We acquire businesses that are not performing optimally in their current environment. With more than 100 carve-outs and M&A transactions done by our team, we have extensive experience in building and executing even challenging carve-outs quickly and effectively.

Potential for international breakthroughs

Most companies seeking international growth have similar challenges: limited funding, challenges in building international sales channels, as well as a need for a more professional approach to the board of directors’ work. In other words, there are hindrances and obstacles to growth. We can help.

Core promise

We help carve-outs and growth companies seize and deliver on growth opportunities.

Our values

Reliability, transparency and integrity.

Sustainable Development

We firmly believe that companies operating with Sustainable Development as a driving principle will benefit from preferential market conditions.

News

15.2.2021 CELLINK AB to Acquire GINOLIS OY – Major exit for Verso Fund II

CELLINK AB (publ) has entered into an agreement with the shareholders of Ginolis Oy to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the “Acquisition”). Ginolis Oy is a leading provider of robot-based automation solutions used world-wide to manufacture a variety of medical disposables and point-of-care tests such […]

Download press release.

15.2.2021 CELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis